Brief: Spyre Therapeutics Announces First Participants Dosed In Phase 1 Trial Of Spy001, It's Inflammatory Bowel Disease Treatment
18/06/2024 13:02
June 18 (Reuters) - Spyre Therapeutics Inc SYRE.O :
* SPYRE THERAPEUTICS ANNOUNCES FIRST PARTICIPANTS DOSED IN
PHASE 1
TRIAL OF SPY001, ITS NOVEL HALF-LIFE EXTENDED ANTI-Α4Β7
ANTIBODY, FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
* SPYRE TO PRESENT INTERIM SPY001 DATA BY YEAR-END 2024
* SPYRE THERAPEUTICS: SPY002 REMAINS ON TRACK TO BEGIN
FIRST-IN-HUMAN STUDIES IN H2 OF 2024
Source text for Eikon: ID:nPn3HlrWta
Further company coverage: SYRE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spyre Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
U.S. STOCKS ON THE MOVE-MYR Group, Spyre Therapeutics, AMD
Spyre Therapeutics slips on $350 mln share sale
Brief: Spyre Therapeutics Announces Pricing Of $350.0 Million Public Offering Of Common Stock